RadioGraphics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, R. G.
Right arrow Articles by Ackery, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, R. G.
Right arrow Articles by Ackery, D. M.

RadioGraphics, Vol 9, 271-281, Copyright © 1989 by Radiological Society of North America

ARTICLES

Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone

RG Robinson, GM Blake, DF Preston, AJ McEwan, JA Spicer, NL Martin, AV Wegst and DM Ackery
Department of Diagnostic Radiology, University of Kansas Medical Center, Kansas City.

Two hundred and two patients with bone pain from metastatic cancer were treated with 40 microCi/kg of Sr-89. Patients were followed with pain diaries, records of medication taken, sleep patterns, serial bone scans and a Karnofsky Index. One hundred and thirty-seven patients with adequate followup survived at least 3 months, including 100 with prostate and 28 with breast carcinoma. Eighty of the 100 patients with prostate cancer responded, and 25 of the 28 breast cancer patients improved. Ten patients with prostate cancer and five with breast cancer became pain free. Little hematologic depression was noted. Sr-89 kinetic studies showed that strontium taken up in osteoblastic areas remained for 100 days. The tumor-to-marrow absorbed dose ratio was 10:1.


This article has been cited by other articles:


Home page
 JCOHome page
S.-M. Tu, J. Kim, L. C. Pagliaro, F. Vakar-Lopez, F. C. Wong, S. Wen, R. General, D. A. Podoloff, S.-H. Lin, and C. J. Logothetis
Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy
J. Clin. Oncol., November 1, 2005; 23(31): 7904 - 7910.
[Abstract] [Full Text] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
K. Liepe, R. Runge, and J. Kotzerke
Systemic radionuclide therapy in pain palliation
American Journal of Hospice and Palliative Medicine, November 1, 2005; 22(6): 457 - 464.
[Abstract] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
H. Smith, A. Navani, and S. M. Fishman
Radiopharmaceuticals for palliation of painful osseous metastases
American Journal of Hospice and Palliative Medicine, July 1, 2004; 21(4): 303 - 313.
[Abstract] [PDF]

Home page
 J Am Acad Orthop SurgHome page
H. J. Siegel, J. V. Luck Jr, and M. E. Siegel
Advances in Radionuclide Therapeutics in Orthopaedics
J. Am. Acad. Ortho. Surg., January 1, 2004; 12(1): 55 - 64.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
A. D. AARON
Current Concepts Review - Treatment of Metastatic Adenocarcinoma of the Pelvis and the Extremities
J. Bone Joint Surg. Am., June 1, 1997; 79(6): 917 - 32.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOGRAPHICS RADIOLOGY RSNA JOURNALS ONLINE
Copyright © 1989 by the Radiological Society of North America.